Loading...

Purified anti-β-Amyloid, 17-24 Antibody (Previously Covance catalog# SIG-39220)

Pricing & Availability
Clone
4G8 (See other available formats)
Regulatory Status
RUO
Workshop
HCDM listed
Other Names
AAA, ABETA, ABPP, AD1, APPI, CTFgamma, CVAP, PN-II, PN2, Amyloid beta A4 protein, preA4, protease nexin-II, peptidase nexin-II, beta-amyloid peptide, alzheimer disease amyloid protein, cerebral vascular amyloid peptide, APP, Amyloid Precursor Protein
Previously
Signet Catalog# 9220-02
Signet Catalog# 9220-05
Signet Catalog# 9220-10
Covance Catalog# SIG-39220
Isotype
Mouse IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
4G8_Pure_Beta-Amyloid_Ascites_Antibody_1_070218
IHC staining of purified anti-β-Amyloid, 17-24 antibody (clone 4G8) on formalin-fixed paraffin-embedded human Alzheimer's disease brain tissue. Following antigen retrieval using 88% formic acid for 20 minutes at room temperature, the tissue was incubated with 1 µg/ml of the primary antibody for 60 minutes at room temperature. BioLegend´s Ultra-Streptavidin (USA) HRP kit (Multi-Species, DAB, Cat. No. 929901) was used for detection followed by hematoxylin counterstaining, according to the protocol provided. The image was captured with a 40X objective. Scale bar: 50 µm
  • 4G8_Pure_Beta-Amyloid_Ascites_Antibody_1_070218
    IHC staining of purified anti-β-Amyloid, 17-24 antibody (clone 4G8) on formalin-fixed paraffin-embedded human Alzheimer's disease brain tissue. Following antigen retrieval using 88% formic acid for 20 minutes at room temperature, the tissue was incubated with 1 µg/ml of the primary antibody for 60 minutes at room temperature. BioLegend´s Ultra-Streptavidin (USA) HRP kit (Multi-Species, DAB, Cat. No. 929901) was used for detection followed by hematoxylin counterstaining, according to the protocol provided. The image was captured with a 40X objective. Scale bar: 50 µm
  • 4G8_Pure_Beta-Amyloid_Ascites_Antibody_2_070218
    IHC staining of purified anti-β-Amyloid, 17-24 antibody (clone 4G8) on formalin-fixed paraffin-embedded human Alzheimer's disease brain tissue. Following antigen retrieval using 88% formic acid for 20 minutes at room temperature, the tissue was incubated with 1 µg/ml of the primary antibody for 60 minutes at room temperature. BioLegend´s Ultra-Streptavidin (USA) HRP kit (Multi-Species, DAB, Cat. No. 929901) was used for detection followed by hematoxylin counterstaining, according to the protocol provided. The image was captured with a 40X objective. Scale bar: 50 µm
  • 4G8_Pure_Beta-Amyloid_Ascites_Antibody_3_070218
    Direct ELISA of purified anti-β-Amyloid, 17-24 (clone 4G8) antibody binding to the plate-immobilized human Aβ1-40, human Aβ1-42, rodent Aβ1-42 peptides, and recombinant human APP751 protein. ELISA was performed by coating the wells with 100 ng of peptide or recombinant protein. The wells were then incubated with the primary antibody at 37°C for 45 minutes, followed by incubation with HRP labeled goat anti-mouse IgG secondary antibody. TMB (3, 3', 5, 5' tetramethylbenzidine, Cat. No. 421501) was used as the detection system.
Compare all formats
Cat # Size Price Quantity Check Availability Save
800712 25 µL $112
Check Availability


Need larger quantities of this item?
Request Bulk Quote
800701 200 µL $554
Check Availability


Need larger quantities of this item?
Request Bulk Quote
800702 500 µL $1083
Check Availability


Need larger quantities of this item?
Request Bulk Quote
800703 1 mL $1780
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Alzheimer’s disease is characterized by the accumulation of aggregated Aβ peptides in senile plaques and vascular deposits. Aβ peptides are derived from amyloid precursor proteins (APP) through sequential proteolytic cleavage of APP by β-secretases and γ-secretases generating diverse Aβ species. Aβ can aggregate to form soluble oligomeric species and insoluble fibrillar or amorphous assemblies. Some forms of the aggregated peptides are toxic to neurons.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human, Mouse
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
Phosphate-buffered solution (no preservatives or carrier proteins).
Preparation
The antibody was purified by affinity chromatography.
Concentration
1 mg/ml
Storage & Handling
This antibody should be handled aseptically as it is free of preservatives such as Sodium Azide. Store this antibody undiluted between 2°C and 8°C. Please note the storage condition for this antibody has been changed from -20°C to between 2°C and 8°C. You can also check the vial label or CoA to find the proper storage conditions.
Application

IHC-P - Quality tested
Direct ELISA - Verified
IHC-F, ICC, IP - Reported in the literature, not verified in house
Recommended Usage

Each lot of this antibody is quality control tested by formalin-fixed paraffin-embedded immunohistochemical staining. For immunohistochemistry, a concentration range of 1.0 - 2.0 µg/ml is suggested. For Direct ELISA applications, a concentration range of 0.15 - 0.5 µg/mL is recommended. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

This antibody is reactive to amino acid residues 17-24 of ß amyloid. The epitope lies within amino acids 18-22 of ß amyloid (VFFAE). 4G8 ß-amyloid antibody reacts to abnormally processed isoforms, as well as precursor forms.

This antibody clone has been reported for use on IHC of free-floating sections in PBS containing 1% Triton incubated with 0.1 m citrate buffer (4).

Additional reported applications (for the relevant formats) include: immunohistochemical staining on frozen tissue sections (IHC-F) and immunocytochemistry (ICC)

Additional Product Notes

View more applications data for this product in our Scientific Poster Library.

Application References

(PubMed link indicates BioLegend citation)
  1. Poduslo JF, et al. 2004. Biochem. 43:6064. (IHC-F) PubMed
  2. Forny-Germano L, et al. 2014. J Neurosci. 34:13629. (IHC-Other) PubMed
  3. Vallino Costassa E, et al. 2016. J Alzheimers Dis. 51: 875-87. (IHC-P) PubMed
  4. Chen X, et al. 2013. Neurobiol Aging. 34:2370. (ICC) PubMed
  5. Hatami A, et al. 2016. J Alzheimers Dis. 50:517. (IHC-P) PubMed
  6. Kawarabayashi T, et al. 2001. J Neurosci 21:372 (IP)
  7. Fonte V, et al. 2002. PNAS. 110:4853 (IP)
Product Citations
  1. Jovic M, et al. 2019. PLoS One. 14:e0216726. PubMed
  2. Illouz T, et al. 2021. Vaccine. 39:4817. PubMed
  3. Schober R, et al. 2021. Neuropathology. 41:366. PubMed
  4. Abrahamson EE, et al. 2022. Brain. 145:2161. PubMed
  5. Wirianto M, et al. 2022. FASEB J. 36:e22186. PubMed
  6. Yeap J, et al. 2022. Brain Neurosci Adv. 6:23982128221086464. PubMed
  7. Melikyan ZA, et al. 2022. Neurobiol Aging. 116:12. PubMed
  8. Feilen LP, et al. 2022. Elife. 11: . PubMed
  9. Yu WS, et al. 2022. Ann N Y Acad Sci. 1515:249. PubMed
  10. Wang Q, et al. 2022. Brain. 145:4474. PubMed
  11. Lucot KL, et al. 2022. Comp Med. 72:267. PubMed
  12. Grochowska KM, et al. 2023. EMBO J. 42:e112453. PubMed
  13. Rudan Njavro J, et al. 2022. Cells. 12: . PubMed
  14. De Schepper S, et al. 2023. Nat Neurosci. 26:406. PubMed
  15. Moon HJ, et al. 2022. Neurobiol Dis. 164:105631. PubMed
  16. Dahl MJ, et al. 2022. Neurobiol Aging. 112:39. PubMed
  17. Xiong J, et al. 2022. Nature. 603:470. PubMed
  18. Bishay J, et al. 2022. Sci Rep. 12:15287. PubMed
  19. Libard S, et al. 2022. J Alzheimers Dis. 90:1601. PubMed
  20. Williams D, et al. 2023. Sci Rep. 13:2337. PubMed
  21. Natarajan C, et al. 2023. Int J Mol Sci. 24:. PubMed
  22. Campbell NB, et al. 2023. Int J Mol Sci. 24:. PubMed
  23. Lia A, et al. 2023. Nat Commun. 14:1590. PubMed
  24. Jiang Y, et al. 2022. Nat Aging. 2:616. PubMed
  25. Woelfle S, et al. 2023. BMC Biol. 21:113. PubMed
  26. Crivelli SM, et al. 2021. Alzheimers Res Ther. 13:45. PubMed
  27. Kretner B, et al. 2016. EMBO Mol Med. 10.15252/emmm.201505952. PubMed
  28. Lutzenberger M, et al. 2015. PLoS One. 10: 0134228. PubMed
  29. Finke JM, et al. 2017. Biochim Biophys Acta. 1861:2228. PubMed
  30. Forny-Germano L, et al. 2014. J Neurosci. 34:13629-13643. PubMed
  31. Doustar J, et al. 2020. Aging Cell. :e13246. PubMed
  32. Sun F, et al. 2020. Front Cell Dev Biol. 8:565020. PubMed
  33. Iacono D, et al. 2020. J Neuropathol Exp Neurol. 79:144. PubMed
  34. Jäkel L, et al. 2019. Acta Neuropathol Commun. 7:141. PubMed
  35. Braak H, et al. 2018. Cereb Cortex. 28:3372. PubMed
  36. Lisa Dolfe et al. 2018. Journal of Alzheimer's disease reports. 2(1):27-39 . PubMed
  37. González C, et al. 2018. Mol Psychiatry. 23:2363. PubMed
  38. Smith AM, et al. 2021. Acta Neuropathol. Online ahead of print. PubMed
  39. Cao KJ, et al. 2021. Transl Vis Sci Technol. 10:5. PubMed
  40. A Kimura, S Hata, T Suzuki 2016. J Biol Chem. 291: 24041 - 24053. PubMed
  41. Keable A, et al. 2016. Biochim Biophys Acta. 1862:1037-1046. PubMed
  42. Chiang ACA, et al. 2018. Am J Pathol. 188:739. PubMed
  43. Zhang L, et al. 2018. Neurobiol Dis. 114:01:00. PubMed
  44. Trambauer J, et al. 2020. EMBO Rep. 21:e47996. PubMed
  45. Elmer BM, et al. 2019. PLoS One. 14:e0226245. PubMed
  46. Wu C, et al. 2020. Med Sci Sports Exerc. 52:1456. PubMed
  47. Rush T, et al. 2018. J Neurosci. 38:10349. PubMed
  48. Osborne C, et al. 2018. J Cell Sci. 131:. PubMed
  49. Kim E, et al. 2021. Biomolecules. 11:. PubMed
  50. Wang C, et al. 2022. Front Pharmacol. 12:763866. PubMed
  51. Guo X, et al. 2020. Aging Dis. 1.446527778. PubMed
  52. Colvin BA, et al. 2017. J Neurochem. 143:736. PubMed
  53. Guan Z, et al. 2020. Front Cell Neurosci. 0.763888889. PubMed
  54. Uhlmann RE, et al. 2020. Nat Neurosci. 23:1580. PubMed
  55. Liu L, et al. 2017. Sci Rep. 7:40467. PubMed
  56. Mo D, et al. 2020. Cells. 9:00. PubMed
  57. Zhang H, et al. 2021. Protein Cell. 12:695. PubMed
  58. Benbow SJ, et al. 2020. Hum Mol Genet. 495:29. PubMed
  59. Fenyi A, et al. 2021. Cells. 10:. PubMed
  60. Nuvolone M, et al. 2017. PLoS One. 12:e0171923. PubMed
  61. Romani M, et al. 2021. Cell Reports. 34(3):108660. PubMed
  62. Shi H, et al. 2020. Acta Neuropathol. 139:813. PubMed
  63. Furukawa F, et al. 2018. Prion. 12:315. PubMed
  64. Wang ZH, et al. 2021. Prog Neurobiol. 202:102032. PubMed
  65. Yamamoto S, et al. 2021. npj Science of Food. 5(1):1. PubMed
  66. Wu Y, et al. 2019. Nat Commun. 10:58. PubMed
  67. Lauretti E, et al. 2017. Ann Clin Transl Neurol. 4:564. PubMed
  68. Puzzo D, et al. 2020. Journal of Clinical Investigation. 130(9):4831-4844. PubMed
  69. Kim E, et al. 2021. Sci Rep. 11:12419. PubMed
  70. Mol MO, et al. 2021. Neurol Genet. 7:e596. PubMed
  71. Sherman M, et al. 2016. J Neurosci. 36: 9647 - 9658. PubMed
  72. Natunen T, et al. 2020. Mol Neurodegener. 0.670833333. PubMed
  73. Garcia–Esparcia P, et al. 2017. Front Neurol. 8:89. PubMed
  74. Eimer WA et al. 2018. Neuron. 99(1):56-63 . PubMed
  75. Lee JH, et al. 2022. Nat Neurosci. 25:688. PubMed
  76. Cacciottolo M, et al. 2017. Transl Psychiatry. 7:e1022. PubMed
  77. Lian H, et al. 2016. J Neurosci. 36: 577 - 589. PubMed
  78. Zhang J, et al. 2019. Aging Cell. 18:e12978. PubMed
  79. Li JG, et al. 2019. Mol Psychiatry. 10.1038/s41380-019-0364-x. PubMed
  80. Plá V, et al. 2017. Front Mol Neurosci. 10:202. PubMed
  81. Grant MKO, et al. 2019. PLoS One. 14:e0212815. PubMed
  82. Liu XC, et al. 2021. Front Aging Neurosci. 13:639318. PubMed
  83. Liu S, et al. 2022. J Neuroinflammation. 19:35. PubMed
  84. Shimada H, et al. 2022. Cell Rep Methods. 2:100289. PubMed
  85. Iacono D, et al. 2018. Parkinsonism Relat Disord. 58:63. PubMed
  86. Zhao P, et al. 2019. Front Behav Neurosci. 13:138. PubMed
  87. Saber M, et al. 2021. J Neurosci Res. 99:1136. PubMed
  88. Lu J, et al. 2021. EMBO Rep. 22:e52013. PubMed
  89. Kaneshiro N, et al. 2022. iScience. 25:103869. PubMed
  90. Fassler M, et al. 2021. J Neuroinflammation. 18:19. PubMed
  91. Prpar Mihevc S, et al. 2019. Front Neurosci. 13:604. PubMed
  92. Carrillo-Jiménez A, et al. 2019. Cell Rep. 29:697. PubMed
  93. Van Skike CE, et al. 2021. J Neurosci. 41:4305. PubMed
  94. Podracky CJ, et al. 2021. Nat Chem Biol. 17:317. PubMed
  95. Fixemer S, et al. 2022. Acta Neuropathol Commun. 10:36. PubMed
  96. Sau-Yeen Loke, Peter Tsun-Hon Wong, Wei-Yi Ong 2017. Neurochem Int. 102:33-56. PubMed
  97. Shi H, et al. 2020. Acta Neuropathol Commun. 0.473611111. PubMed
  98. Jäkel L, et al. 2020. Mol Neurobiol. 57:2131. PubMed
  99. Meilandt WJ, et al. 2020. J Neurosci. 40:1956. PubMed
  100. Harper MM, et al. 2019. Invest Ophthalmol Vis Sci. 60:2716. PubMed
  101. Kim S, et al. 2019. Int J Mol Sci. 20. PubMed
  102. Zhu B, et al. 2022. Chem Sci. 13:8104. PubMed
  103. Kim S, et al. 2020. Int J Mol Sci. 21:00. PubMed
  104. Ezpeleta J, et al. 2019. Nat Commun. 10:3442. PubMed
  105. Pires G, et al. 2019. Acta Neuropathol Commun. 0.427083333. PubMed
  106. Wang ZH, et al. 2019. Cell Rep. 28:655. PubMed
  107. Lee KH, et al. 2017. Yonsei Med J. 58:1055. PubMed
  108. Libard S, et al. 2021. J Alzheimers Dis. 80:1003. PubMed
  109. Espinoza S, et al. 2022. Cells. 11:. PubMed
  110. Prpar Mihevc S, et al. 2020. Front Vet Sci. 7:573155. PubMed
  111. Xu G, et al. 2020. Acta Neuropathol Commun. 8:43. PubMed
  112. Luo R, et al. 2020. Autophagy. 16:52. PubMed
  113. Song JX, et al. 2020. Aging Cell. 19:e13069. PubMed
  114. Li JG, et al. 2020. Mol Neurodegener. 15:01. PubMed
  115. Wang B, et al. 2017. Mol Psychiatry. 22:990. PubMed
  116. Carranza-Naval MJ, et al. 2022. Front Aging Neurosci. 13:741923. PubMed
  117. Jonson M, et al. 2018. Cell Chem Biol. 25:595. PubMed
  118. West E, et al. 2017. J Cell Sci. 130:3050. PubMed
  119. Rayaprolu S, et al. 2020. Mol Neurodegener. 15:28. PubMed
  120. Rivera I, et al. 2018. Cell Stress Chaperones. 23:269. PubMed
  121. Wang W et al. 2019. EBioMedicine. 42:174-187 . PubMed
  122. Catania M, et al. 2022. Mol Psychiatry. :. PubMed
  123. Lo Cascio F, et al. 2020. J Biol Chem. 295:14807. PubMed
RRID
AB_2734548 (BioLegend Cat. No. 800712)
AB_2564633 (BioLegend Cat. No. 800701)
AB_2564634 (BioLegend Cat. No. 800702)
AB_662812 (BioLegend Cat. No. 800703)

Antigen Details

Structure
Amyloid precursor protein is a 770 amino acid protein with a molecular mass of ~100 kD. According to the UniProtKB database, APP (ID# P05067) has 11 isoforms (34 to ~90 kD) and the 770 form has been designated as the canonical form. Isoform APP695 is the predominant form expressed in neuronal tissue. Isoforms APP751 and APP770 are widely expressed in non-neuronal cells. Isoform APP751 is the most abundant form in T-lymphocytes. Aβ denotes peptides of 36-43 amino acids generated from cleavage of APP by secretases. Aβ has an apparent molecular mass of about 4 kD.
Distribution

Tissue distribution: Primarily nervous system, but also adipose tissue, intestine, and muscle.
Cellular distribution: Cytosol, endosomes, nucleus, plasma membrane, extracellular, and golgi apparatus.

Function
The normal function of Aβ is not well understood. Several potential physiological roles have been proposed, including: activation of kinase enzymes; protection against oxidative stress; regulation of cholesterol transport; transcription factor, and as an anti-microbial agent.
Biology Area
Cell Biology, Neurodegeneration, Neuroscience, Protein Misfolding and Aggregation
Molecular Family
APP/β-Amyloid
Antigen References
  1. Kumar A, et al. 2015. Pharmacol Rep. 67(2):195.
  2. Sadigh-Eteghad S, et al. 2015. Med Princ Pract. 24(1):1
  3. Hampel H, et al. 2015. Expert Rev Neruother. 15(1):83.
  4. Puig KL, et al. 2012. Exp Gerontol. 48(7): 608.
  5. Selkoe DJ, et al. 2016. EMBO Mol Med. 8(6):595.
  6. Walsh DM, et al.  2007. J Neurochem. 101(5):1172.
Gene ID
351 View all products for this Gene ID
Specificity (DOES NOT SHOW ON TDS):
beta-Amyloid 17-24
Specificity Alt (DOES NOT SHOW ON TDS):
β-Amyloid, 17-24
App Abbreviation (DOES NOT SHOW ON TDS):
IHC-P,Direct ELISA,IHC-F,ICC,IP
UniProt
View information about beta-Amyloid 17-24 on UniProt.org
Go To Top Version: 6    Revision Date: 12/16/2021

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account